Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (NASDAQ: IMGN) and Zynerba Pharmaceuticals (NASDAQ: ZYNE)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ImmunoGen (NASDAQ: IMGN) and Zynerba Pharmaceuticals (NASDAQ: ZYNE).

ImmunoGen (NASDAQ: IMGN)

In a report released today, Boris Peaker from Cowen & Co. reiterated a Hold rating on ImmunoGen (NASDAQ: IMGN). The company’s shares opened today at $3.75.

Peaker observed:

“IMGN presented data from mrive’s Phase I biopsy expansion cohort at SGO.”

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, and Merrimack Pharmaceuticals.

Currently, the analyst consensus on ImmunoGen is Moderate Buy and the average price target is $5, representing a 33.3% upside.

In a report issued on March 2, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $5 price target.
Zynerba Pharmaceuticals (NASDAQ: ZYNE)

In a report released today, Lauren Chung from Maxim Group reiterated a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE), with a price target of $32. The company’s shares opened today at $20.30.

Chung wrote:

“Zynerba announced completion of enrollment in both the phase II STAR I (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) trial for ZYN002 in adult refractory focal seizures, and phase II STOP (Synthetic Transdermal Cannbidiol for the Treatment of Knee Pain due to Osteoarthritis) trial in osteoarthritis.”

According to TipRanks.com, Chung is ranked #3276 out of 4517 analysts.

Zynerba Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.